Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401182 | 1.00 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL29458423 | 1.00 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL887559 | 1.00 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL1660910 | 0.99 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL230688 | 0.94 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29468684 | 0.94 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31031901 | 0.94 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.94 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5TLR2 | |
| SCHEMBL163534 | 0.89 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL15160681 | 0.88 | KMT2A (0.75) | KMT2AEPHX2FABP7FABP5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| EP-3743517-B1 | SEQUENCING ADDITIVE | QIAGEN SCIENCES LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024040169-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2024-02-22 | — | — | WO | disclosed |
| US-11821032-B2 | DNA sequencing reaction additive | IsoPlexis Corporation (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230340583-A1 | DNA SEQUENCING REACTION ADDITIVE | IsoPlexis Corporation | 2023-10-26 | — | — | US | disclosed |
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20140206595-A1 | CLEANING MIXTURE FOR THE REMOVAL OR AVOIDANCE OF INSECT DEPOSITS ON SURFACES | EADS DEUTSCHLAND GMBH (DE) | 2014-07-24 | — | — | US | disclosed |
| EP-2746378-A1 | Cleaning mixture for removing or preventing deposits from insects on surfaces | EADS Deutschland GmbH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014068443-A1 | SPLICEOSTATIN ANALOGS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013170077-A2 | V1A RECEPTOR AGONISTS | FERRING B.V. (NL) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013116682-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| US-6764768-B2 | SELF ASSEMBLING MONOLAYERS OF ALKANETHIOLATES | ARCH DEVELOPMENT CORPORATION | 2004-07-20 | — | — | US | disclosed |
| US-20020119305-A1 | Controlled release composition | ARCH DEVELOPMENT CORPORATION | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | KMT2A 1507/4885EPHX2 3793/4885FABP7 3357/4885 |
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL23R | KMT2A 1164/4885EPHX2 1524/4885FABP7 4099/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | KMT2A 2167/4885EPHX2 2080/4885FABP7 1242/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
| US-11821032-B2 | DNA sequencing reaction additive | RNGTT, NSUN2, NT5C3B | KMT2A 2077/4885EPHX2 2123/4885FABP7 3838/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
| US-20230340583-A1 | DNA SEQUENCING REACTION ADDITIVE | RNGTT, NSUN2, NT5C3B | KMT2A 2077/4885EPHX2 2123/4885FABP7 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.